Skip to main content
NewslettersWatchlist

Bausch & Lomb Corp(BLCO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low14.31
Day High14.68
Open:14.32
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
This Bausch Health Companies Unusually Active Option Is a No-Brainer
ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
PR Newswire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
ACCESSWIRE
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
Business Wire
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance
Business Wire
Bausch + Lomb Releases Annual Environmental, Social and Governance Report
Business Wire
Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting
Business Wire
Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results
Business Wire
Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System
Business Wire
Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting
Business Wire
Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
Business Wire
Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3
Business Wire
Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform
Business Wire
Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals
Business Wire
Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology
Business Wire
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
Business Wire
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
Business Wire
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients
Business Wire
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
Business Wire
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
Business Wire
Bausch + Lomb Acquires AcuFocus, Inc.
Business Wire
Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™
Business Wire
Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference
Business Wire
Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference
Business Wire
Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology
Business Wire
Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month
Motley Fool
Why Bausch Health Stock Is Jumping Today
Motley Fool
Bausch + Lomb Corporation (BLCO) Q2 2022 Earnings Call Transcript
Motley Fool
Why Bausch Health Stock Is Bolting Higher Today

Profile

Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R). Bausch Lomb Corporation is based in VAUGHAN, ON.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.